This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Papamichael, D. Search for Related Content PubMed PubMed Citation Articles by Papamichael, D.

The Use of Thymidylate Synthase Inhibitors in the Treatment of Advanced Colorectal Cancer: Current Status

Cyprus Oncology Centre, Strovolos, Nicosia, Cyprus

Correspondence: D. Papamichael, M.B., B.S. (London) MRCP (U.K.), Consultant Medical Oncologist, Cyprus Oncology Centre, 32 Acropoleos Avenue, 2006 Strovolos, Nicosia, Cyprus. Telephone: 00357-2-841400; Fax: 00357-2-511870; e-mail: dpapamic{at}logos.cy.net

The combination of 5-fluorouracil (5-FU) and leucovorin has been the unofficial "standard" therapy for patients with colorectal cancer for over a decade. Recently, however, a number of new agents targeted against the enzyme thymidylate synthase have been synthesized and are in various stages of development. The currently available thymidylate synthase inhibitors are discussed.

Enormous efforts have been made over the years to improve the efficacy of 5-FU, the most popular of these agents. Biochemical modulation by leucovorin has been the most successful so far. Continuous infusion schedules also appear to be advantageous over bolus administration. However, marked intra- and interpatient variability, combined with nonlinear elimination kinetics and erratic oral bioavailability are relative limitations to further development of 5-FU. New oral 5-FU prodrugs such as UFT, S-1, and Capecitabine may help to overcome some of these difficulties. Eniluracil, a potent inhibitor of the enzyme dihydropyrimidine dehydrogenase, may also help by overcoming potential 5- FU resistance mechanisms, in addition to increasing its bioavailability. Of the antifolate-based inhibitors, Tomudex is in the most advanced stage of development. Similar efficacy with 5-FU and a convenient schedule may suggest a role in future combination regimens.

It is quite likely that even the most optimal thymidylate synthase inhibition will have limitations in terms of clinical efficacy. Novel combinations of 5-FU or its analogs with agents that have different mechanisms of action (e.g., oxaliplatin, irinotecan) could provide important new opportunities for improving the outlook of patients with colorectal cancer.

Key Words. Thymidylate synthase • 5-Fluorouracil • S-1 • UFT • Capecitabine • Raltitrexed • MTA

This article has been cited by other articles:

				J. Geller, I. Petak, K. S. Szucs, K. Nagy, D. M. Tillman, and J. A. Houghton Interferon-{gamma}-Induced Sensitization of Colon Carcinomas to ZD9331 Targets Caspases, Downstream of Fas, Independent of Mitochondrial Signaling and the Inhibitor of Apoptosis Survivin Clin. Cancer Res., December 15, 2003; 9(17): 6504 - 6515. [Abstract] [Full Text] [PDF]

				M. V. Mandola, J. Stoehlmacher, S. Muller-Weeks, G. Cesarone, M. C. Yu, H.-J. Lenz, and R. D. Ladner A Novel Single Nucleotide Polymorphism within the 5' Tandem Repeat Polymorphism of the Thymidylate Synthase Gene Abolishes USF-1 Binding and Alters Transcriptional Activity Cancer Res., June 1, 2003; 63(11): 2898 - 2904. [Abstract] [Full Text] [PDF]

				R. W. Berg, M. Werner, P. J. Ferguson, C. Postenka, M. Vincent, D. J. Koropatnick, and E. Behrend Tumor Growth Inhibition in Vivo and G2/M Cell Cycle Arrest Induced by Antisense Oligodeoxynucleotide Targeting Thymidylate Synthase J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 477 - 484. [Abstract] [Full Text] [PDF]